Form 8-K - Current report:
SEC Accession No. 0001493152-22-012630
Filing Date
2022-05-10
Accepted
2022-05-10 09:22:03
Documents
16
Period of Report
2022-05-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 51184
2 ex10-1.htm EX-10.1 124090
3 ex10-2.htm EX-10.2 54820
4 ex99-1.htm EX-99.1 15909
5 ex99-1_001.jpg GRAPHIC 3514
  Complete submission text file 0001493152-22-012630.txt   469565

Data Files

Seq Description Document Type Size
6 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prph-20220509.xsd EX-101.SCH 3045
7 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prph-20220509_lab.xml EX-101.LAB 34476
8 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prph-20220509_pre.xml EX-101.PRE 22603
10 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3717
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 22907642
SIC: 2834 Pharmaceutical Preparations